<DOC>
	<DOCNO>NCT00490620</DOCNO>
	<brief_summary>This proof principal study determine whether combination anti-viral therapy Combivir impact hepatic biochemistry patient primary biliary cirrhosis</brief_summary>
	<brief_title>Study Combivir Patients With Primary Biliary Cirrhosis</brief_title>
	<detailed_description>A novel human retrovirus clone cDNA library derive biliary epithelium cell extract patient Primary Biliary Cirrhosis . Although formal proof virus etiologically related disease , find evidence viral infection majority patient PBC use standard serologic hybridization assay . In order address hypotheses PBC etiologically related retrovirus infection anti-retroviral therapy may beneficial patient PBC , conduct 2 pilot study use lamivudine Combivir ( lamivudine 150mg Zidovudine 300mg ) . On whole , little clinical improvement observe patient lamivudine therapy alone , whereas Combivir significant reduction hepatic biochemistry study histologic improvement . Moreover , 4 10 Combivir patient completely normalize liver function test anti-viral therapy well tolerate . We propose large randomize trial ass short term ( 6 month ) safety efficacy Combivir patient PBC . Efficacy study define use liver biochemistry virologic endpoint .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<criteria>Patients 18 year old either sex recruit study . Persistently elevate alkaline phosphatase serum aminotransferases least 1.5 time normal minimum 6 month UDCA therapy . Positive serum AMA ( titer &gt; 1:20 ) . Liver biopsy histology compatible PBC obtain time prior study . Maintained UDCA dose 1315 mg/kg 6 month . Patients must read sign informed consent form . Patients treat immunosuppressive antiinflammatory agent colchicine , methotrexate , Dpenicillamine , cyclosporine , tacrolimus , mycophenolate mofetil , corticosteroid therapy exclude may enter study 3 month period immunosuppressive antiinflammatory therapy . Advanced liver disease : Childs Pugh class B C cirrhosis , recurrent variceal hemorrhage , spontaneous encephalopathy , diuretic resistant ascites , need liver transplantation within year . Patients secondary hepatic diagnosis viral hepatitis , drug induce liver injury , extrahepatic biliary obstruction , primary sclerosing cholangitis , metabolic liver diseases alcoholic liver disease . Regular use 30 g alcohol per day last year . Patients predict survival less 3 year malignant potentially life threaten disease . Creatinine clearance less &lt; 70 mL/min use Cockcroft Gault equation : Clinically apparent pancreatitis . Serum amylase &gt; 3 x upper limit normal ( patient sicca syndrome salivary gland disease may elevate amylase level ) Pregnancy breastfeed child . Sexually active patient child bear age use effective contraception . Allergic reaction Combivir like drug Clinical evidence myositis Weight &lt; 50 Kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>primary biliary cirrhosis C06.552.630.400</keyword>
	<keyword>retroviral infection C02.782.815</keyword>
</DOC>